ArticleInternational journal of hematology2021
Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan.
Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 38 citations in OpenAlex.
- When Liver Disease Misleads the Diagnosis: Two Cases of TAFRO Syndrome With Porto-Sinusoidal Vascular Disease.EJHaem · 2026Article
- Interleukin-6 levels decrease following rituximab treatment but increase following tocilizumab treatment.Annals of hematology · 2026Article
- Article
- Ruxolitinib in relapsed/refractory TAFRO syndrome: a report of two cases, including one positive for Epstein-Barr virus, and a literature review.International journal of hematology · 2026Review
- Successful Treatment of Refractory TAFRO Syndrome with Cyclophosphamide: A Report of Two Cases.Internal medicine (Tokyo, Japan) · 2025Article
- Serum Soluble Interleukin-2 Receptor as a Potential Marker for Assessing Disease Activity in the TAFRO Subtype of Idiopathic Multicentric Castleman Disease.Internal medicine (Tokyo, Japan) · 2025Article
- Multicentric Castleman disease presenting with orbital involvement progressing to TAFRO syndrome: a case report.BMC ophthalmology · 2025Article
- Response to initial treatment with glucocorticoids in TAFRO syndrome and implications for secondary treatment.International journal of hematology · 2025Article
- TAFRO-like Symptoms in a Sjögren's Syndrome Patient with HTLV-1 Infection.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- Article
- Morphological and quantitative CT features of anterior mediastinal lesions in TAFRO syndrome and idiopathic multicentric Castleman disease.Frontiers in immunology · 2025Article
- TAFRO syndrome requiring combined IL 6 and IL 1 inhibition: a case report.Frontiers in immunology · 2025Article
- Pathophysiology, Treatment, and Prognosis of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome: A Review.Current issues in molecular biology · 2024Review
- TAFRO Syndrome and COVID-19.Biomedicines · 2024Review
- TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly.Biomedicines · 2024Review
- Tacrolimus Treatment for TAFRO Syndrome.Biomedicines · 2024Article
- Stepwise Treatment for TAFRO Syndrome.Journal of medical cases · 2023Article
- Severe TAFRO Syndrome Mimicking Hepatorenal Syndrome Successfully Treated with a Multidisciplinary Approach: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2023Review
- Acute Abdomen and Adrenal Swelling as the First Manifestations of TAFRO Syndrome.Internal medicine (Tokyo, Japan) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
Abstract
TAFRO syndrome is a systemic inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. Mortality in patients with this syndrome is high; however, an optimal treatment strategy has not been established. To explore the strategy, we retrospectively analyzed 81 patients with TAFRO syndrome registered in the Multicenter Collaborative Retrospective Study for Establishing the Concept of TAFRO Syndrome in Japan by December 2019. Sixty-eight patients received corticosteroid therapy as the first-line treatment, and as the second-line treatment, 21 received tocilizumab (Toc), 14 received cyclosporine A (CsA), and 8 received rituximab (Rit) in addition to corticosteroids. We compared these second-line treatment groups by setting the primary endpoint as time to next treatment or death (TTNT). Kaplan-Meier analysis showed that the median TTNT in the Toc, CsA, and Rit groups were 2.8 months, 9.2 months, and not reached, respectively. The TTNT of the Rit group was significantly longer than that of the Toc group. In contrast, there were no significant differences in overall survival between groups, indicating that subsequent salvage therapies rescued a large proportion of patients who failed the second-line treatments. Further studies are warranted to establish the optimal treatment strategies for this syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.